Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 4, 2021
Reporting Period: Event date February 4, 2021
This filing addresses inquiries regarding a Registration Statement on Form S-3 filed on February 3, 2021. The Company clarified that this filing is not a new primary issuance of shares to the public.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a regulatory disclosure regarding securities registration and does not contain financial performance data.
Material Changes
No material financial changes are reported. The filing clarifies the nature of a recent Form S-3 registration statement:
- The Form S-3 is a resale registration statement.
- It pertains to shares owned by existing warrantholders.
- These warrants were issued as part of a registered direct offering completed in July 2018.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a statement to clarify the purpose of the Form S-3 filing in response to market inquiries, ensuring investors understand it does not represent a new capital raise from the Company.
Risks and Contingencies: The filing text does not provide a clear value for new risks, contingencies, or unusual items beyond the clarification of the securities registration.
Investor Verification Checklist
- Verify the details of the Form S-3 filed on February 3, 2021, to confirm it is a resale registration and not a primary offering.
- Review the July 2018 registered direct offering documents to understand the warrant terms being resold.
- Confirm the number of shares held by warrantholders eligible for resale under this registration.